Issues related to compounding and counterfeit drugs.
Source-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- S-3 GROUP
- Client
- NOVO NORDISK, INC.
- Filing UUID
- 1b60a436-1852-42d9-8474-74d9dd5d2371
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing and implementation of the Inflation Reduction Act; coverage of anti-obesity medications; pharmacy benefit management reforms; Most Favored Nation drug pricing.
Issues related to tariffs and importation of counterfeit drugs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.